Literature DB >> 737255

Serotonin, folic acid, and uric acid metabolism in the diagnosis of neuropsychiatric disorders.

S C Brooks, J J Linn, N Disney.   

Abstract

Metabolic compensation appears possible within the serotonergic, folate, purine system and it seems possible that clinical illness may result when the system can no longer compensate. For example, elevated serotonin, induced by stress accumulation of tryptophan, could be compensated by a lowered folate ratio, normalizing the beta-carboline index and preventing hallucinations. Conversely, deficient serotonin, induced by a psychological loss or transport deficit, could be compensated by raising the folate ratio, which would normalize the beta-carboline index and prevent further depression. Increased purine turnover would seemingly lower the folate ratio, compensating perhaps for hallucinatory activity or mania. Several genetic defects of enzymes or transport proteins could seemingly preclude normal compensations within the system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 737255

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

2.  Some indices of the catecholamine and indoleamine metabolism in groups of patients with paranoid and simple forms of schizophrenia.

Authors:  N B Gamaleya
Journal:  Neurosci Behav Physiol       Date:  1985 Mar-Apr

3.  Biomolecular information analysis in neurotransmitter systems.

Authors:  S C Brooks
Journal:  Acta Biotheor       Date:  1984       Impact factor: 1.774

4.  Are Uric Acid Levels Different from Healthy Subjects in Bipolar Affective Disorder and Schizophrenia?: Relationship Between Clinical Improvement and Episode Severity in Male Patients.

Authors:  Bülent Kadri Gültekin; Sermin Kesebir; Sevgi Gül Kabak; Ferzan Fikret Ergün; Elif Tatlidil Yaylaci
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

Review 5.  Genetics and schizophrenic behavior.

Authors:  E Kahn
Journal:  Psychiatr Q       Date:  1980

Review 6.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

7.  Reduced urinary serotonin excretion after intake of high doses of hypoxanthine.

Authors:  H Manzke; H Gustmann
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

8.  A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania.

Authors:  Rodrigo Machado-Vieira; Jair C Soares; Diogo R Lara; David A Luckenbaugh; João V Busnello; Getulio Marca; Angelo Cunha; Diogo O Souza; Carlos A Zarate; Flavio Kapczinski
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

9.  Clinical potential of allopurinol in the treatment of bipolar disorder.

Authors:  Ram J Bishnoi
Journal:  Indian J Psychol Med       Date:  2014-04

10.  Comparison of Serum Uric Acid in Major Depressive Disorder and Bipolar Disorder: a Retrospective Chart Review Study.

Authors:  Soomin Kim; Sang Jin Rhee; Yoojin Song; Yong Min Ahn
Journal:  J Korean Med Sci       Date:  2020-07-20       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.